

Hematological Malignancies Emerging Therapeutics Market - A Global and Regional Analysis: Focus on Therapeutic Type (Marketed), Potential Pipeline Products, Indication, and Region - Analysis and Forecast, 2021-2031

<https://marketpublishers.com/r/H79A248D28A0EN.html>

Date: February 2022

Pages: 258

Price: US\$ 5,250.00 (Single User License)

ID: H79A248D28A0EN

Abstracts

Market Report Coverage - Hematological Malignancies Emerging Therapeutics

Market Segmentation

Marketed Drugs - Monoclonal Antibodies and CAR-T Cell Therapy

Potential Pipeline Products - Monoclonal Antibodies and CAR-T Cell Therapy

Indication - Leukemia, Lymphoma, and Multiple Myeloma

Regional Segmentation

North America - U.S. and Canada

Europe - Germany, U.K., France, Italy, and Spain

Asia-Pacific - China, Japan, and South Korea

Rest-of-the-World

Market Growth Drivers

Growing Prevalence of Hematological Malignancies

Favorable Regulatory Environment

Increase in Adoption of Precision Medicine in the Field of Hematological Malignancies

Market Challenges

High Cost Hindering the Adoption Rate

Unfavorable Reimbursement Scenario

Safety Concerns Pertaining to Severe Adverse Effects

Market Opportunities

Massive Scope in Emerging Markets

Key Companies Profiled

AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited

Key Questions Answered in this Report:

What are the major market drivers, challenges, and opportunities in the global hematological malignancies emerging therapeutics market?

What are the underlying structures resulting in the emerging trends within the global hematological malignancies emerging therapeutics market?

How has the COVID-19 pandemic impacted the global hematological malignancies emerging therapeutics ecosystem?

What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?

What is the pricing and reimbursement scenario in the field of hematological malignancies emerging therapeutics?

What are the potential emerging therapies present in the pipeline for hematological malignancy treatment?

What are the key regulatory implications in developed and developing regions pertaining to hematological malignancies emerging therapeutics?

What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?

How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments mentioned below:

Marketed Drugs (Monoclonal Antibodies and CAR-T Cell Therapy)

Potential Pipeline Products

Indication (Leukemia, Lymphoma, and Multiple Myeloma)

Region (North America, Europe, Asia-Pacific, and Rest-of-the-World)

What is the role of companion diagnostics in the field of hematological malignancies emerging therapies? What are the key regulatory requirements associated with companion diagnostics?

What are the growth opportunities for the companies in the region of their operation?

Who are the leading players with significant offerings in the global hematological malignancies emerging therapeutics market?

Which companies are anticipated to be highly disruptive in the future, and why?

Market Overview

The global hematological malignancies emerging therapeutics industry analysis by BIS Research projects the market to grow at a significant CAGR of 14.20% during the forecast period 2021-2031. The hematological malignancies emerging therapeutics market was valued at \$11,652.5 million in 2021 and is expected to generate \$43,966.8 million in 2031.

The hematological malignancies emerging therapeutics market growth has been primarily attributed to major drivers in this market, such as growing prevalence of hematological malignancies, favorable regulatory environment, and increase in adoption of precision medicine in the field of hematological malignancies. However, there are significant challenges restraining the market growth. These challenges include the high cost hindering the adoption rate, unfavorable reimbursement scenario, and safety concerns pertaining to severe adverse effects.

The hematological malignancies emerging therapeutics market report provides a holistic view of the market in terms of various factors influencing it, including reported clinical findings, financing and partnership opportunities, expected market, and current clinical landscape.

The report constitutes an in-depth study of the global hematological malignancies emerging therapeutics market. The study consists of monoclonal antibody (mAB)- and chimeric antigen receptor (CAR) T-cell-based therapies intended for the treatment of hematological malignancies. The study also presents a detailed analysis of the market dynamics and estimation of the market size over the forecast period, 2021-2031.

The scope of this report is focused on the analysis of the hematological malignancies emerging therapeutics market by therapeutic type (marketed), potential pipeline products, indication, and region. The market value may vary from 5-7% as the data has been collected from different sources at the regional and country level.

Contents

1 MARKET

1.1 Product Definition

- 1.1.1 Monoclonal Antibody (mAB) Therapy: Hematological Malignancies
- 1.1.2 CAR-T Cell Therapy: Hematological Malignancies
- 1.1.3 Inclusion and Exclusion

1.2 Market Scope

- 1.2.1 Key Questions Answered in the Report

1.3 Research Methodology

1.3.1 Global Hematological Malignancy Emerging Therapeutics Market: Research Methodology

1.3.2 Data Sources

- 1.3.2.1 Primary Data Sources
- 1.3.2.2 Secondary Data Sources

1.3.3 Market Estimation Model

1.3.4 Criteria for Company Profiling

1.4 Market Overview

1.4.1 Market Definition

1.4.2 Market Footprint and Growth Potential, \$Million, 2020-2031

1.4.3 Epidemiology of Hematological Malignancies

- 1.4.3.1 U.S. Epidemiology of Hematological Malignancies
- 1.4.3.2 Epidemiology of Hematological Malignancies (Germany, France, Italy, and Spain (EU4) + U.K.)

1.4.3.3 Japan Epidemiology of Hematological Malignancies

1.4.4 Pipeline Analysis

1.4.4.1 By Clinical Phase

1.4.4.2 By Indication

1.4.4.2.1 Leukemia

1.4.4.2.2 Lymphoma

1.4.4.2.3 Multiple Myeloma (MM)

1.4.5 Impact of COVID-19 on Global Hematological Malignancies Emerging Therapeutics Market

1.4.5.1 Interruption in Research and Clinical Development and Commercial Operation

1.4.5.1.1 Research and Clinical Development

1.4.5.1.2 Commercial Operation and Access

1.4.5.2 Navigating Crisis Recovery and Looking to the Future

2 INDUSTRY ANALYSIS

2.1 Overview

2.2 Legal Requirements and Frameworks in the U.S.

2.2.1 Clinical Trial Authorization

2.2.2 Marketing Authorization

2.2.3 Post-Authorization Regulations

2.3 Legal Requirements and Frameworks in Europe

2.3.1 Centralized Procedure

2.3.2 Decentralized Procedure

2.3.3 Mutual-Recognition Procedure

2.3.4 National Procedure

2.4 Legal Requirements and Frameworks in Asia-Pacific

2.4.1 China

2.4.2 Japan

2.5 Reimbursement Scenario

2.5.1 U.S.

2.5.2 Europe

3 MARKET DYNAMICS

3.1 Overview

3.2 Impact Analysis

3.3 Market Drivers

3.3.1 Growing Prevalence of Hematological Malignancies

3.3.2 Favorable Regulatory Environment

3.3.3 Increase in Adoption of Precision Medicine in the Field of Hematological Malignancies

3.4 Market Restraints

3.4.1 High Cost Hindering the Adoption Rate

3.4.2 Unfavorable Reimbursement Scenario

3.4.3 Safety Concerns Pertaining to Severe Adverse Effects

3.5 Market Opportunities

3.5.1 Massive Scope in Emerging Markets

4 COMPETITIVE LANDSCAPE

4.1 Overview

4.2 Key Developments and Strategies

- 4.2.1 Partnerships and Alliances
- 4.2.2 Regulatory and Legal Activities
- 4.2.3 Business Expansions
- 4.2.4 Merger and Acquisition Activities
- 4.2.5 Product Approvals
- 4.2.6 Funding Activities
- 4.3 Market Share Analysis, by Company (2020)

5 ROLE OF COMPANION DIAGNOSTICS

- 5.1 Overview
- 5.2 Drug-Diagnostic Co-Development
- 5.3 FDA-Approved Companion Diagnostic Tests for Hematological Malignancies
- 5.4 Regulatory Framework: Companion Diagnostics (CDx)
 - 5.4.1 Overview
 - 5.4.2 Legal Requirements and Frameworks in the U.S.
 - 5.4.3 Legal Requirements and Frameworks in Europe
 - 5.4.4 Legal Requirements and Frameworks in Asia-Pacific
 - 5.4.4.1 China
 - 5.4.4.2 Japan
 - 5.4.4.3 South Korea
 - 5.4.4.4 Australia

6 GLOBAL HEMATOLOGICAL MALIGNANCIES EMERGING THERAPEUTICS MARKET (BY MARKETED DRUGS), \$MILLION, 2020-2031

- 6.1 Overview
- 6.2 Monoclonal Antibodies
 - 6.2.1 Blincyto (Blinatumomab)
 - 6.2.2 Besponsa (Inotuzumab Ozogamicin)
 - 6.2.3 Lumoxiti (Moxetumomab Pasudotox)
 - 6.2.4 Mylotarg (Gemtuzumab Ozogamicin)
 - 6.2.5 Opdivo (Nivolumab)
 - 6.2.6 AiRuiKa (Camrelizumab)
 - 6.2.7 Tyvyt (Sintilimab)
 - 6.2.8 Tislelizumab
 - 6.2.9 Gazyva (Obinutuzumab)
 - 6.2.10 Zynlonta (Loncastuximab Tesirine-lpyl)
 - 6.2.11 Darzalex (Daratumumab)

- 6.2.12 Blenrep (Belantamab Mafodotin-blmf)
- 6.2.13 Keytruda (Pembrolizumab)
 - 6.2.13.1 Keytruda for Indication 1 (Hodgkin's Lymphoma)
 - 6.2.13.2 Keytruda for Indication 2 (Non-Hodgkin's Lymphoma)
- 6.2.14 Adcetris (Brentuximab Vedotin)
 - 6.2.14.1 Adcetris for Indication 1 (Hodgkin's Lymphoma)
 - 6.2.14.2 Adcetris for Indication 2 (Non-Hodgkin's Lymphoma)
- 6.2.15 Arzerra (Ofatumumab)
- 6.3 CAR-T Cell Therapy
 - 6.3.1 Tecartus (Brexucabtagene Autoleucl)
 - 6.3.1.1 Tecartus for Indication 1 (Acute Lymphoblastic Leukemia)
 - 6.3.1.2 Tecartus for Indication 2 (Non-Hodgkin's Lymphoma)
 - 6.3.2 Kymriah (Tisagenlecleucl)
 - 6.3.2.1 Kymriah for Indication 1 (Acute Lymphoblastic Leukemia)
 - 6.3.2.2 Kymriah for Indication 2 (Non-Hodgkin's Lymphoma)
 - 6.3.3 Yescarta (Axicabtagene Ciloleucl)
 - 6.3.4 Breyanzi (Lisocabtagene Maraleucl)
 - 6.3.5 Abecma (Idecabtagene Vicleucl)

7 GLOBAL HEMATOLOGICAL MALIGNANCIES EMERGING THERAPEUTICS MARKET (BY POTENTIAL PIPELINE PRODUCTS), \$MILLION, 2020-2031

- 7.1 Overview
- 7.2 Monoclonal Antibodies
 - 7.2.1 Teclistamab
 - 7.2.2 Iomab-B
 - 7.2.2.1 Preliminary Phase II Clinical Trial Results
 - 7.2.3 Ublituximab
 - 7.2.4 CS1001
- 7.3 CAR-T Cell Therapy
 - 7.3.1 Ciltacabtagene Autoleucl (JNJ-68284528)
 - 7.3.1.1 Phase IB-II Clinical Trial Results

8 GLOBAL HEMATOLOGICAL MALIGNANCIES EMERGING THERAPEUTICS MARKET (BY INDICATION), \$MILLION, 2020-2031

- 8.1 Overview
- 8.2 Leukemia
 - 8.2.1 Acute Lymphoblastic Leukemia

- 8.2.2 Chronic Lymphoblastic Leukemia
- 8.2.3 Acute Myeloid Leukemia
- 8.3 Lymphoma
 - 8.3.1 Hodgkin's Lymphoma
 - 8.3.2 Non-Hodgkin's Lymphoma
- 8.4 Multiple Myeloma

9 GLOBAL HEMATOLOGICAL MALIGNANCIES EMERGING THERAPEUTICS MARKET (BY REGION), \$MILLION, 2020-2031

- 9.1 Overview
- 9.2 North America
 - 9.2.1 U.S.
 - 9.2.1.1 Commercialized Products
 - 9.2.1.2 Market Size and Forecast, \$Million, 2020-2031
 - 9.2.2 Canada
 - 9.2.2.1 Commercialized Products
 - 9.2.2.2 Market Size and Forecast, \$Million, 2020-2031
- 1.2 Europe
 - 9.2.3 Germany
 - 9.2.3.1 Market Size and Forecast, \$Million, 2020-2031
 - 9.2.4 Italy
 - 9.2.4.1 Market Size and Forecast, \$Million, 2020-2031
 - 9.2.5 France
 - 9.2.5.1 Market Size and Forecast, \$Million, 2020-2031
 - 9.2.6 U.K.
 - 9.2.6.1 Market Size and Forecast, \$Million, 2020-2031
 - 9.2.7 Spain
 - 9.2.7.1 Market Size and Forecast, \$Million, 2020-2031
- 9.3 Asia-Pacific
 - 9.3.1 China
 - 9.3.1.1 Commercialized Products
 - 9.3.1.2 Market Size and Forecast, \$Million, 2020-2031
 - 9.3.2 Japan
 - 9.3.2.1 Commercialized Products
 - 9.3.2.2 Market Size and Forecast, \$Million, 2020-2031
 - 9.3.3 South Korea
 - 9.3.3.1 Commercialized Products
 - 9.3.3.2 Market Size and Forecast, \$Million, 2020-2031

9.4 Rest-of-the-World

10 COMPANY PROFILES

10.1 Overview

10.2 AbbVie Inc.

10.2.1 Company Overview

10.2.2 Role of AbbVie Inc. in the Global Hematological Malignancies Emerging Therapeutics Market

10.2.3 Financials

10.2.4 Key Insights About Financial Health of the Company

10.2.5 SWOT Analysis

10.3 Amgen Inc.

10.3.1 Company Overview

10.3.2 Role of Amgen Inc. in the Global Hematological Malignancies Emerging Therapeutics Market

10.3.3 Financials

10.3.4 Key Insights About Financial Health of the Company

10.3.5 SWOT Analysis

10.4 Bristol-Myers Squibb Company

10.4.1 Company Overview

10.4.2 Role of Bristol-Myers Squibb Company in the Global Hematological Malignancies Emerging Therapeutics Market

10.4.3 Financials

10.4.4 Key Insights About Financial Health of the Company

10.4.5 SWOT Analysis

10.5 F. Hoffmann-La Roche Ltd.

10.5.1 Company Overview

10.5.2 Role of F. Hoffmann-La Roche Ltd. in the Global Hematological Malignancies Emerging Therapeutics Market

10.5.3 Financials

10.5.4 Key Insights About Financial Health of the Company

10.5.5 SWOT Analysis

10.6 Gilead Sciences, Inc.

10.6.1 Company Overview

10.6.2 Role of Gilead Sciences, Inc. in the Global Hematological Malignancies Emerging Therapeutics Market

10.6.3 Financials

10.6.4 Key Insights About Financial Health of the Company

- 10.6.5 SWOT Analysis
- 10.7 GlaxoSmithKline plc
 - 10.7.1 Company Overview
 - 10.7.2 Role of GlaxoSmithKline plc in the Global Hematological Malignancies Emerging Therapeutics Market
 - 10.7.3 Financials
 - 10.7.4 Key Insights About Financial Health of the Company
 - 10.7.5 SWOT Analysis
- 10.8 Immune-Onc Therapeutics, Inc.
 - 10.8.1 Company Overview
 - 10.8.2 Role of Immune-Onc Therapeutics, Inc. in the Global Hematological Malignancies Emerging Therapeutics Market
 - 10.8.3 SWOT Analysis
- 10.9 Johnson & Johnson Services, Inc.
 - 10.9.1 Company Overview
 - 10.9.2 Role of Johnson & Johnson Services, Inc. in the Global Hematological Malignancies Emerging Therapeutics Market
 - 10.9.3 Financials
 - 10.9.4 Key Insights About Financial Health of the Company
 - 10.9.5 SWOT Analysis
- 10.1 Merck & Co., Inc.
 - 10.10.1 Company Overview
 - 10.10.2 Role of Merck & Co., Inc. in the Global Hematological Malignancies Emerging Therapeutics Market
 - 10.10.3 Financials
 - 10.10.4 Key Insights About Financial Health of the Company
 - 10.10.5 SWOT Analysis
- 10.11 Novartis International AG
 - 10.11.1 Company Overview
 - 10.11.2 Role of Novartis International AG in the Global Hematological Malignancies Emerging Therapeutics Market
 - 10.11.3 Financials
 - 10.11.4 Key Insights About Financial Health of the Company
 - 10.11.5 SWOT Analysis
- 10.12 Pfizer Inc.
 - 10.12.1 Company Overview
 - 10.12.2 Role of Pfizer Inc. in the Global Hematological Malignancies Emerging Therapeutics Market
 - 10.12.3 Financials

10.12.4 Key Insights About Financial Health of the Company

10.12.5 SWOT Analysis

10.13 Sanofi S.A.

10.13.1 Company Overview

10.13.2 Role of Sanofi S.A. in the Global Hematological Malignancies Emerging

Therapeutics Market

10.13.3 Financials

10.13.4 Key Insights About Financial Health of the Company

10.13.5 SWOT Analysis

10.14 Takeda Pharmaceutical Company Limited

10.14.1 Company Overview

10.14.2 Role of Takeda Pharmaceutical Company Limited in the Global Hematological

Malignancies Emerging Therapeutics Market

10.14.3 Financials

10.14.4 Key Insights About Financial Health of the Company

10.14.5 SWOT Analysis

List Of Figures

LIST OF FIGURES

Figure 1: Hematological Malignancies Drugs Approved by U.S. FDA (2015-2021)

Figure 2: Hematological Malignancies Drugs Global Clinical Trials (by Phase)

Figure 3: Global Hematological Malignancies Emerging Therapeutics Market (by Marketed Drugs), \$Million, 2020-2031

Figure 4: Global Hematological Malignancies Emerging Therapeutics Market: Impact Analysis

Figure 5: Global Hematological Malignancies Emerging Therapeutics Market (by Potential Pipeline Products), \$Million, 2020-2031

Figure 6: Global Hematological Malignancies Emerging Therapeutics Market (by Indication), \$Million, 2020-2031

Figure 7: Global Hematological Malignancies Emerging Therapeutics Market (by Region), \$Million, 2020-2031

Figure 8: Global Hematological Malignancies Emerging Therapeutics Market: Segmentation

Figure 9: Global Hematological Malignancies Emerging Therapeutics Market: Methodology

Figure 10: Primary Research Methodology

Figure 11: Bottom-Up Approach (Segment-Wise Analysis)

Figure 12: Step by Step Approach

Figure 13: Global Hematological Malignancies Emerging Therapeutics Market, \$Million, 2020-2031

Figure 14: Types of Hematological Malignancies

Figure 15: Hematological Malignancies Prevalence in the U.S., 2019-2031

Figure 16: Hematological Malignancies Incidence in the U.S., 2019-2031

Figure 17: Percentage of Hematological Malignancies Prevalence (by Country), 2019 and 2031

Figure 18: Hematological Malignancies Prevalence in EU4+U.K., 2019-2031

Figure 19: Percentage of Hematological Malignancies Incidence (by Country), 2019 and 2031

Figure 20: Hematological Malignancies Incidence in EU4 + U.K., 2019-2031

Figure 21: Hematological Malignancies Prevalence in Japan, 2019-2031

Figure 22: Hematological Malignancies Incidence in Japan, 2019-2031

Figure 23: Hematological Malignancies Emerging Therapies: Developmental Phases

Figure 24: Emerging Therapeutics for Leukemia (by Developmental Phase)

Figure 25: Emerging Therapeutics for Lymphoma (by Developmental Phase)

Figure 26: Emerging Therapeutics for Multiple Myeloma (by Developmental Phase)

Figure 27: Key Steps to Navigate Crisis Recovery

Figure 28: Process for Obtaining Marketing Authorization

Figure 29: Current Reimbursement Scenario in Europe

Figure 30: Prevalence of Hematological Malignancies (2015-2019)

Figure 31: Share of Key Developments and Strategies, January 2019-December 2021

Figure 32: Partnerships and Alliances (by Company), January 2019-December 2021

Figure 33: Regulatory and Legal Activities (by Company), January 2019-December 2021

Figure 34: Business Expansions (by Company), January 2019-December 2021

Figure 35: Merger and Acquisition Activities (by Company), January 2019-December 2021

Figure 36: Product Approvals (by Company), January 2019-December 2021

Figure 37: Market Share Analysis (by Company), 2020

Figure 38: Drug-Diagnostic Co-Development Model

Figure 39: FDA Guidance Pertaining to CDx Approval

Figure 40: Components Considered for Clinical Evidence as per the IVDR

Figure 41: Medical Device Regulatory Approval Process in China

Figure 42: Process of Medical Device Designation by MHLW and PMDA

Figure 43: Medical Device Regulatory Approval Process in South Korea

Figure 44: Classification of IVD Devices

Figure 45: Medical Device (IVDs) Regulatory Approval Process in Australia

Figure 46: Global Hematological Malignancies Emerging Therapeutics Market (by Marketed Drugs), \$Million, 2020-2031

Figure 47: Global Hematological Malignancies Emerging Therapeutics Market (by Monoclonal Antibodies), \$Million, 2020-2031

Figure 48: Global Revenue for Blincyto, \$Million, 2020-2031

Figure 49: Global Revenue for Besponsa, \$Million, 2020-2031

Figure 50: Global Revenue for Lumoxiti, \$Million, 2020-2031

Figure 51: Global Revenue for Mylotarg, \$Million, 2020-2031

Figure 52: Global Revenue for Opdivo, \$Million, 2020-2031

Figure 53: Global Revenue for AiRuiKa, \$Million, 2020-2031

Figure 54: Global Revenue for Tyvyt, \$Million, 2020-2031

Figure 55: Global Revenue for Tislelizumab, \$Million, 2020-2031

Figure 56: Global Revenue for Gazyva, \$Million, 2020-2031

Figure 57: Global Revenue for Zynlonta, \$Million, 2020-2031

Figure 58: Global Revenue for Darzalex, \$Million, 2020-2031

Figure 59: Global Revenue for Blenrep, \$Million, 2020-2031

Figure 60: Global Revenue for Keytruda, \$Million, 2020-2031

Figure 61: Global Revenue for Keytruda (Hodgkin's Lymphoma), \$Million, 2020-2031

Figure 62: Global Revenue for Keytruda (Non-Hodgkin's Lymphoma), \$Million, 2020-2031

Figure 63: Global Revenue for Adcetris, \$Million, 2020-2031

Figure 64: Global Revenue for Adcetris (Hodgkin's Lymphoma), \$Million, 2020-2031

Figure 65: Global Revenue for Adcetris (Non-Hodgkin's Lymphoma), \$Million, 2020-2031

Figure 66: Global Hematological Malignancies Emerging Therapeutics Market (by CAR-T Cell Therapy), \$Million, 2020-2031

Figure 67: Global Revenue for Tecartus, \$Million, 2020-2031

Figure 68: Global Revenue for Tecartus (Acute Lymphoblastic Leukemia), \$Million, 2020-2031

Figure 69: Global Revenue for Tecartus (Non-Hodgkin's Lymphoma), \$Million, 2020-2031

Figure 70: Global Revenue for Kymriah, \$Million, 2020-2031

Figure 71: Global Revenue for Kymriah (Acute Lymphoblastic Leukemia), \$Million, 2020-2031

Figure 72: Global Revenue for Kymriah (Non-Hodgkin's Lymphoma), \$Million, 2020-2031

Figure 73: Global Revenue for Yescarta, \$Million, 2020-2031

Figure 74: Global Revenue for Breyanzi, \$Million, 2020-2031

Figure 75: Global Revenue for Abecma, \$Million, 2020-2031

Figure 76: Global Hematological Malignancies Emerging Therapeutics Market (by Potential Pipeline Products), \$Million, 2020-2031

Figure 77: Global Hematological Malignancies Emerging Therapeutics Market (by Potential Pipeline Products), by Monoclonal Antibodies), \$Million, 2020-2031

Figure 78: Global Revenue for Teclistamab, \$Million, 2020-2031

Figure 79: Teclistamab Phase I Clinical Trial Design for Relapsed or Refractory Multiple Myeloma

Figure 80: Teclistamab Phase II Clinical Trial Design for Relapsed or Refractory Multiple Myeloma

Figure 81: Global Revenue for Iomab-B, \$Million, 2020-2031

Figure 82: Iomab-B Phase III Clinical Trial Design for Relapsed or Refractory Acute Myeloid Leukemia

Figure 83: Global Revenue for Ublituximab, \$Million, 2020-2031

Figure 84: Ublituximab Phase I/II Clinical Trial Design for Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Figure 85: Global Revenue for CS1001, \$Million, 2020-2031

Figure 86: CS1001 Phase II Clinical Trial Design for Relapsed or Refractory B-cell

Hodgkin's Lymphoma

Figure 87: Global Revenue for Ciltacabtagene Autoleucel, \$Million, 2020-2031

Figure 88: Ciltacabtagene Autoleucel (JNJ-68284528) Phase Ib-II Clinical Trial Design for Relapsed or Refractory Multiple Myeloma

Figure 89: Global Hematological Malignancies Emerging Therapeutics Market (by Indication), \$Million, 2020-2031

Figure 90: Global Hematological Malignancies Emerging Therapeutics Market (by Indication, by Leukemia), \$Million, 2020-2031

Figure 91: Global Hematological Malignancies Emerging Therapeutics Market (by Acute Lymphoblastic Leukemia), \$Million, 2020-2031

Figure 92: Global Hematological Malignancies Emerging Therapeutics Market (by Chronic Lymphoblastic Leukemia), \$Million, 2020-2031

Figure 93: Global Hematological Malignancies Emerging Therapeutics Market (by Acute Myeloid Leukemia), \$Million, 2020-2031

Figure 94: Global Hematological Malignancies Emerging Therapeutics Market (by Lymphoma), \$Million, 2020-2031

Figure 95: Global Hematological Malignancies Emerging Therapeutics Market (by Hodgkin's Lymphoma), \$Million, 2020-2031

Figure 96: Global Hematological Malignancies Emerging Therapeutics Market (by Non-Hodgkin's Lymphoma), \$Million, 2020-2031

Figure 97: Global Hematological Malignancies Emerging Therapeutics Market (by Multiple Myeloma), \$Million, 2020-2031

Figure 98: Global Hematological Malignancies Emerging Therapeutics Market (by Region), \$Million, 2020-2031

Figure 99: North America Hematological Malignancies Emerging Therapeutics Market, \$Million, 2020-2031

Figure 100: North America: Market Dynamics

Figure 101: North America Hematological Malignancies Emerging Therapeutics Market, (by Country), \$Million, 2020 and 2031

Figure 102: U.S. Hematological Malignancies Emerging Therapeutics Market, \$Million, 2020-2031

Figure 103: Canada Hematological Malignancies Emerging Therapeutics Market, \$Million, 2020-2031

Figure 104: Europe Hematological Malignancies Emerging Therapeutics Market, \$Million, 2020-2031

Figure 105: Europe: Market Dynamics

Figure 106: Europe Hematological Malignancies Emerging Therapeutics Market, (by Country), \$Million, 2020 and 2031

Figure 107: Germany Hematological Malignancies Emerging Therapeutics Market,

\$Million, 2020-2031

Figure 108: Italy Hematological Malignancies Emerging Therapeutics Market, \$Million, 2020-2031

Figure 109: France Hematological Malignancies Emerging Therapeutics Market, \$Million, 2020-2031

Figure 110: U.K. Hematological Malignancies Emerging Therapeutics Market, \$Million, 2020-2031

Figure 111: Spain Hematological Malignancies Emerging Therapeutics Market, \$Million, 2020-2031

Figure 112: Asia-Pacific Hematological Malignancies Emerging Therapeutics Market, \$Million, 2020-2031

Figure 113: Asia-Pacific: Market Dynamics

Figure 114: Asia-Pacific Hematological Malignancies Emerging Therapeutics Market (by Country), \$Million, 2020 and 2031

Figure 115: China Hematological Malignancies Emerging Therapeutics Market, \$Million, 2020-2031

Figure 116: Japan Hematological Malignancies Emerging Therapeutics Market, \$Million, 2020-2031

Figure 117: South Korea Hematological Malignancies Emerging Therapeutics Market, \$Million, 2020-2031

Figure 118: Rest-of-the-World Hematological Malignancies Emerging Therapeutics Market, \$Million, 2020-2031

Figure 119: Total Number of Companies Profiled

Figure 120: AbbVie Inc.: Pre-Clinical and Clinical Assets

Figure 121: AbbVie Inc.: Overall Financials, \$Million, 2018-2020

Figure 122: AbbVie, Inc.: Revenue (by Region), \$Million, 2018-2020

Figure 123: AbbVie Inc.: R&D Expenditure, \$Million, 2018-2020

Figure 124: AbbVie Inc.: SWOT Analysis

Figure 125: Amgen Inc.: Commercialized Therapy

Figure 126: Amgen Inc.: Pre-Clinical and Clinical Assets

Figure 127: Amgen Inc.: Overall Financials, \$Million, 2018-2020

Figure 128: Amgen Inc.: Revenue (by Region), \$Million, 2018-2020

Figure 129: Amgen Inc.: R&D Expenditure, \$Million, 2018-2020

Figure 130: Amgen Inc.: SWOT Analysis

Figure 131: Bristol-Myers Squibb Company: Commercialized Therapies

Figure 132: Bristol-Myers Squibb Company: Pre-Clinical and Clinical Assets

Figure 133: Bristol-Myers Squibb Company: Overall Financials, \$Million, 2018-2020

Figure 134: Bristol-Myers Squibb Company: Revenue (by Region), \$Million, 2018-2020

Figure 135: Bristol-Myers Squibb Company: R&D Expenditure, \$Million, 2018-2020

- Figure 136: Bristol-Myers Squibb Company: SWOT Analysis
- Figure 137: F. Hoffmann-La Roche Ltd.: Commercialized Therapy
- Figure 138: F. Hoffmann-La Roche Ltd.: Pre-Clinical and Clinical Assets
- Figure 139: F. Hoffmann-La Roche Ltd.: Overall Financials, \$Million, 2018-2020
- Figure 140: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), \$Million, 2018-2020
- Figure 141: F. Hoffmann-La Roche Ltd.: Revenue (by Region), \$Million, 2018-2020
- Figure 142: F. Hoffmann-La Roche Ltd.: R&D Expenditure, \$Million, 2018-2020
- Figure 143: F. Hoffmann-La Roche Ltd.: SWOT Analysis
- Figure 144: Gilead Sciences, Inc.: Commercialized Therapies
- Figure 145: Gilead Sciences, Inc.: Pre-Clinical and Clinical Assets
- Figure 146: Gilead Sciences, Inc.: Overall Financials, \$Million, 2018-2020
- Figure 147: Gilead Sciences, Inc.: Revenue (by Segment), \$Million, 2018-2020
- Figure 148: Gilead Sciences, Inc.: Revenue (by Region), \$Million, 2018-2020
- Figure 149: Gilead Sciences, Inc.: R&D Expenditure, \$Million, 2018-2020
- Figure 150: Gilead Sciences, Inc.: SWOT Analysis
- Figure 151: GlaxoSmithKline plc: Commercialized Therapy
- Figure 152: GlaxoSmithKline plc: Overall Financials, \$Million, 2018-2020
- Figure 153: GlaxoSmithKline plc: Revenue (by Segment), \$Million, 2018-2020
- Figure 154: GlaxoSmithKline plc: Revenue (by Region), \$Million, 2018-2020
- Figure 155: GlaxoSmithKline plc: R&D Expenditure, \$Million, 2018-2020
- Figure 156: GlaxoSmithKline plc: SWOT Analysis
- Figure 157: Immune-Onc Therapeutics, Inc.: Pre-Clinical and Clinical Assets
- Figure 158: Immune-Onc Therapeutics, Inc.: SWOT Analysis
- Figure 159: Johnson & Johnson Services, Inc.: Commercialized Therapy
- Figure 160: Johnson & Johnson Services, Inc.: Pre-Clinical and Clinical Assets
- Figure 161: Johnson & Johnson Services, Inc.: Overall Financials, \$Million, 2018-2020
- Figure 162: Johnson & Johnson Services, Inc.: Revenue (by Segment), \$Million, 2018-2020
- Figure 163: Johnson & Johnson Services, Inc.: Revenue (by Region), \$Million, 2018-2020
- Figure 164: Johnson & Johnson Services, Inc.: R&D Expenditure, \$Million, 2018-2020
- Figure 165: Johnson & Johnson Services, Inc.: SWOT Analysis
- Figure 166: Merck & Co., Inc.: Commercialized Therapy
- Figure 167: Merck & Co., Inc.: Pre-Clinical and Clinical Assets
- Figure 168: Merck & Co., Inc.: Overall Financials, \$Million, 2018-2020
- Figure 169: Merck & Co., Inc.: Revenue (by Segment), \$Million, 2018-2020
- Figure 170: Merck & Co., Inc.: Revenue (by Region), \$Million, 2018-2020
- Figure 171: Merck & Co., Inc.: R&D Expenditure, \$Million, 2018-2020
- Figure 172: Merck & Co., Inc.: SWOT Analysis

- Figure 173: Novartis International AG: Commercialized Therapy
- Figure 174: Novartis International AG: Pre-Clinical and Clinical Assets
- Figure 175: Novartis International AG: Overall Financials, \$Million, 2018-2020
- Figure 176: Novartis International AG: Revenue (by Segment), \$Million, 2018-2020
- Figure 177: Novartis International AG: Revenue (by Region), \$Million, 2018-2020
- Figure 178: Novartis International AG: R&D Expenditure, \$Million, 2018-2020
- Figure 179: Novartis International AG: SWOT Analysis
- Figure 180: Pfizer Inc.: Commercialized Therapy
- Figure 181: Pfizer Inc.: Pre-Clinical and Clinical Assets
- Figure 182: Pfizer Inc.: Overall Financials, \$Million, 2018-2020
- Figure 183: Pfizer Inc.: Revenue (by Region), \$Million, 2018-2020
- Figure 184: Pfizer Inc.: R&D Expenditure, \$Million, 2018-2020
- Figure 185: Pfizer Inc.: SWOT Analysis
- Figure 186: Sanofi S.A.: Pre-Clinical and Clinical Assets
- Figure 187: Sanofi SA: Overall Financials, \$Million, 2018-2020
- Figure 188: Sanofi S.A.: Revenue (by Segment), \$Million, 2018-2020
- Figure 189: Sanofi S.A.: Revenue (by Region), \$Million, 2018-2020
- Figure 190: Sanofi S.A.: R&D Expenditure, \$Million, 2018-2020
- Figure 191: Sanofi S.A.: SWOT Analysis
- Figure 192: Takeda Pharmaceutical Company Limited.: Commercialized Therapy
- Figure 193: Takeda Pharmaceutical Company Limited: Pre-Clinical and Clinical Assets
- Figure 194: Takeda Pharmaceutical Company Limited: Overall Financials, \$Million, 2018-2020
- Figure 195: Takeda Pharmaceutical Company Limited: Revenue (by Region), \$Million, 2018-2020
- Figure 196: Takeda Pharmaceutical Company Limited: R&D Expenditure, \$Million, 2018-2020
- Figure 197: Takeda Pharmaceutical Company Limited: SWOT Analysis

List Of Tables

LIST OF TABLES

- Table 1: Cost of Selective Hematological Malignancies Therapeutics in U.S.
- Table 2: Likert Scale
- Table 3: Impact Analysis of Market Drivers
- Table 4: Impact Analysis of Market Restraints
- Table 5: Prominent FDA-Approved CDx Tests for Hematological Malignancies
- Table 6: Classification Rules of IVDs under IVDR
- Table 7: Registration Criteria for IVD Medical Devices as per the NMPA
- Table 8: Hematological Malignancies Therapeutics Drugs for Acute Lymphoblastic Leukemia
- Table 9: Hematological Malignancies Therapeutics Drugs for Chronic Lymphoblastic Leukemia
- Table 10: Hematological Malignancies Therapeutics Drugs for Acute Myeloid Leukemia
- Table 11: Hematological Malignancies Therapeutics Drugs for Hodgkin's Lymphoma
- Table 12: Hematological Malignancies Therapeutics Drugs for Non-Hodgkin's Lymphoma
- Table 13: Hematological Malignancies Therapeutics Drugs for Multiple Myeloma
- Table 14: List of Selective Hematological Malignancies Commercialized Products in the U.S.
- Table 15: Canada Hematological Malignancies Commercialized Products
- Table 16: List of Selective Hematological Malignancies Commercialized Products in Europe
- Table 17: List of Selective Hematological Malignancies Commercialized Products in China
- Table 18: List of Selective Hematological Malignancies Commercialized Products in Japan
- Table 19: List of Selective Hematological Malignancies Commercialized Products in South Korea
- Table 20: Blincyto (Blinatumomab): Indications
- Table 21: Opdivo (Nivolumab) and Breyanzi (Lisocabtagene Maraleucel): Indications
- Table 22: Gazyva (Obinutuzumab): Indications
- Table 23: Yescarta (Axicabtagene ciloleucel) and Tecartus (Brexucabtagene autoleucel): Indications
- Table 24: Blenrep (Belantamab mafodotin): Indications
- Table 25: Darzalex (Daratumumab): Indications
- Table 26: Keytruda (Pembrolizumab): Indications

Table 27: Kymriah (Tisagenlecleucel): Indications

Table 28: Besponsa (Inotuzumab ozogamicin) and Mylotarg (Gemtuzumab Ozogamicin): Indications

Table 29: Adcetris (Brentuximab vedotin): Indications

I would like to order

Product name: Hematological Malignancies Emerging Therapeutics Market - A Global and Regional Analysis: Focus on Therapeutic Type (Marketed), Potential Pipeline Products, Indication, and Region - Analysis and Forecast, 2021-2031

Product link: <https://marketpublishers.com/r/H79A248D28A0EN.html>

Price: US\$ 5,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H79A248D28A0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970